What question did this study set out to answer?

This review aims to summarize the clinical symptoms and laboratory findings of patients co-infected with dengue virus and SARS-CoV-2.

June 14, 2026BMC Infectious Diseases0 citationsOpen Access

Clinical manifestations and laboratory findings in patients coinfected with dengue virus and SARS-CoV-2: a systematic review

RARahadhyan AdnyanaschahPadjadjaran University RARizky AbdulahPadjadjaran University MOMonika P. OktoraPadjadjaran University

Key Points

This review aims to summarize the clinical symptoms and laboratory findings of patients co-infected with dengue virus and SARS-CoV-2.
Systematic review following PRISMA guidelines
Data collected from PubMed on articles from 2020 to 2025
Included theoretical articles, case reports, case series, and cohort studies.
Fever reported in 69% of co-infected patients
Laboratory findings showed hypotension in 57.14% and tachypnea in 50%
Symptoms of vomiting and abdominal pain occurred in 57% and 55% respectively.

Abstract

Abstract Background Dengue Hemorrhagic Fever and Coronavirus disease 2019 (COVID-19) are infectious diseases caused by dengue virus (DENV) and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). While DENV remains endemic in many tropical regions, SARS-CoV-2 spread globally beginning in 2020. Reports of coinfection have emerged from several countries. This systematic review describes the clinical manifestations and laboratory findings reported in patients coinfected with DENV and SARS-CoV-2. Methods This review followed the PRISMA guidelines and collecting data from PubMed for articles published between 2020 and 2025 that discussed DENV and SARS-CoV-2 coinfection. Eligible study designs included theoretical articles, case reports, case series, and cohort studies. Data were synthesized descriptively due to heterogeneity and the absence of comparator groups. Results Fifteen studies met the inclusion criteria, identifying 65 patients with SARS-CoV-2 and DENV coinfection. Reported symptoms included fever (69%), vomiting (57%), abdominal pain (55%), rash (54%), and shock (51%). Laboratory findings also showed hematological and physiological alterations including hypotension (57.14%), tachypnea (50%), fever (62.5%), neutropenia (33.33%), neutrophilia (50%), lymphopenia (42.86%), and lymphocytosis (28.57%). These percentages represent descriptive counts across heterogeneous case reports and do not reflect prevalence estimates. Conclusions Patients with DENV and SARS-CoV-2 coinfection exhibit a range of clinical and laboratory abnormalities, but the available evidence—primarily case reports and case series without comparator groups—does not allow conclusions about disease severity or prognosis relative to monoinfection. The findings should therefore be interpreted as descriptive and hypothesis-generating. Careful diagnostic evaluation and clinical monitoring remain essential in suspected coinfection cases. Clinical trial number Not applicable.

Ask AI

Helpful

Bookmark

View Full Paper